Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

Angelina Jolie has surprisingly faced a wave of online abuse. Her recent photoshoot for TIME France is now being viewed as an ...

Programme testing for BRCA mutation to resume next year after successful launch results, Health Secretary tells JC ...

Zydus Lifesciences has partnered with US-based Myriad Genetics to bring advanced cancer risk and prognostic tests to India, aiming to boost personalized oncology care.

Zydus partners with Myriad Genetics to introduce advanced cancer-risk assessment tests, enhancing precision diagnostics in India.

RAD51-based assessment effectively identifies HER2-negative metastatic breast cancer patients likely to respond to olaparib, especially with BRCA1/2 or PALB2 variants. RAD51-low tumors showed a higher ...

NEW YORK – The US Food and Drug Administration has approved Latus Bio's investigational new drug application, allowing the firm to begin clinical trials of a gene therapy candidate in patients with ...

Cancer remains a major health burden in Kenya, accounting for about 7% of annual deaths, with an estimated 32,000 deaths and 44,000 new cases each year. The high mortality rate is largely due to late ...

LEWISBURG — Valley residents hoping to discover genetic factors that impact health outcomes can do so at WellSpan Evangelical Community Hospital. WellSpan’s Gene Health Project, in partnership with ...